UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 3, 2007


Date of Report (Date of earliest event reported)

 

NPS PHARMACEUTICALS, INC.


(Exact name of registrant as specified in its charter)


Delaware

 

0-23272

 

87-0439579


 


 


(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification Number)


550 Hills Drive, 3rd Floor

Bedminster, NJ 07921


(Address of principal executive offices)

 

(908) 450-5300


(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



Item 8.01

Other Events.

On October 3, 2007, NPS Pharmaceuticals, Inc. issued a press release announcing an increase in the purchase price of its outstanding 3.0% convertible notes due 2008 (the “Notes”) to $987.50 per $1,000.00 principal amount of the Notes, plus accrued and unpaid interest up to, but not including, the date of payment for the Notes accepted for payment, and an extension of the tender offer until midnight, New York City time, on October 17, 2007. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

99.1

Press Release issued by NPS Pharmaceuticals, Inc. on October 3, 2007 relating to the increase in the tender offer price and extension of tender offer.


SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 3, 2007

NPS PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

By:

/s/ VAL R. ANTCZAK

 

 


 

 

Val R. Antczak, Senior Vice President, Legal Affairs, General Counsel and Secretary


EXHIBIT INDEX

Exhibit No.

 

Description


 


99.1

 

Press Release issued by NPS Pharmaceuticals, Inc. on October 3, 2007 relating to the increase in the tender offer price and extension of tender offer.